Next Article in Journal
Investigations of the Ligand Electronic Effects on α-Diimine Nickel(II) Catalyzed Ethylene Polymerization
Next Article in Special Issue
Interpenetration of Natural Polymer Aerogels by Supercritical Drying
Previous Article in Journal
Artificial Neural Network and Response Surface Methodology Modeling in Ionic Conductivity Predictions of Phthaloylchitosan-Based Gel Polymer Electrolyte
Previous Article in Special Issue
Reversible Self-Assembly of Backbone-Thermoresponsive Long Chain Hyperbranched Poly(N-Isopropyl Acrylamide)
Article Menu

Export Article

Open AccessFeature PaperArticle
Polymers 2016, 8(2), 36; doi:10.3390/polym8020036

l-Cystine-Crosslinked Polypeptide Nanogel as a Reduction-Responsive Excipient for Prostate Cancer Chemotherapy

1,2,†
,
2,†
,
3,* , 2
,
1,2
,
1,2
,
1,* and 2,*
1
Department of Urology, the First Hospital of Jilin University, Changchun 130021, China
2
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
3
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan 250117, China
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Academic Editor: Carsten Werner
Received: 19 December 2015 / Revised: 21 January 2016 / Accepted: 26 January 2016 / Published: 29 January 2016
(This article belongs to the Special Issue Functional Polymers for Medical Applications)
View Full-Text   |   Download PDF [1838 KB, uploaded 29 January 2016]   |  

Abstract

Smart polymer nanogel-assisted drug delivery systems have attracted more and more attention in cancer chemotherapy because of their well-defined morphologies and pleiotropic functions in recent years. In this work, an l-cystine-crosslinked reduction-responsive polypeptide nanogel of methoxy poly(ethylene glycol)-poly(l-phenylalanine-co-l-cystine) (mPEG-P(LP-co-LC)) was employed as a smart excipient for RM-1 prostate cancer (PCa) chemotherapy. Doxorubicin (DOX), as a regular chemotherapy drug, was embedded in the nanogel. The loading nanogel marked as NG/DOX was shown to exhibit glutathione (GSH)-induced swelling and GSH-accelerated DOX release. Subsequently, NG/DOX showed efficient cellular uptake and proliferation inhibition. Furthermore, NG/DOX presented enhanced antitumor efficacy and security in an RM-1 PCa-grafted mouse model in vivo, indicating its great potential for clinical treatment. View Full-Text
Keywords: chemotherapy; l-cystine; polypeptide nanogel; prostate cancer; reduction-responsiveness; smart drug delivery chemotherapy; l-cystine; polypeptide nanogel; prostate cancer; reduction-responsiveness; smart drug delivery
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

He, L.; Li, D.; Wang, Z.; Xu, W.; Wang, J.; Guo, H.; Wang, C.; Ding, J. l-Cystine-Crosslinked Polypeptide Nanogel as a Reduction-Responsive Excipient for Prostate Cancer Chemotherapy. Polymers 2016, 8, 36.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Polymers EISSN 2073-4360 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top